Form 13-F position report

RIGEL PHARMACEUTICALS INC

Reported by CM Management LLC

RIGL CUSIP 766559702 Manager CIK 0001841857

Reported 250,000 shares, unchanged from the prior quarter.

Reported value 23.1%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value 8.08% This manager · Q3 2026
Shares 250,000 Quarter-end amount reported
Reported value $12,037,500 Fair value at quarter end
Consecutive quarters held 24 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 2054000
2022-03-31 2317000
2022-06-30 1469000
2022-09-30 1534000
2022-12-31 2250000
2023-03-31 1980000
2023-06-30 1935000
2023-09-30 1620000
2023-12-31 2465000
2024-03-31 2960000
2024-06-30 0
2024-09-30 4692200
2024-12-31 4078850
2025-03-31 4497500
2025-06-30 4682500
2025-09-30 6374250
2025-12-31 9636750
2026-03-31 6354400
2026-06-30 9780000
2026-09-30 12037500

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for RIGEL PHARMACEUTICALS INC held by CM Management LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Unchanged 250,000 0 (0.0%) 8.08% $12,037,500 2026-11-12
Q2 2026 Added 250,000 +15,000 (6.4%) 6.21% $9,780,000 2026-08-13
Q1 2026 Added 235,000 +10,000 (4.4%) 5.31% $6,354,400 2026-05-08
Q4 2025 Unchanged 225,000 0 (0.0%) 8.12% $9,636,750 2026-02-02
Q3 2025 Reduced 225,000 -25,000 (-10.0%) 5.31% $6,374,250 2025-11-13
Q2 2025 Unchanged 250,000 0 (0.0%) 4.26% $4,682,500 2025-08-12
Q1 2025 Added 250,000 +7,500 (3.1%) 4.52% $4,497,500 2025-05-09
Q4 2024 Reduced 242,500 -47,500 (-16.4%) 3.64% $4,078,850 2025-02-07
Q3 2024 New 290,000 +290,000 (0.0%) 3.74% $4,692,200 2024-11-12
Q2 2024 Reduced 0 -2,000,000 (-100.0%) 0 $0 2024-08-01
Q1 2024 Added 2,000,000 +300,000 (17.6%) 2.49% $2,960,000 2024-05-14
Q4 2023 Added 1,700,000 +200,000 (13.3%) 1.98% $2,465,000 2024-02-12
Q3 2023 Unchanged 1,500,000 0 (0.0%) 1.72% $1,620,000 2023-11-07
Q2 2023 Unchanged 1,500,000 0 (0.0%) 1.89% $1,935,000 2023-08-04
Q1 2023 Unchanged 1,500,000 0 (0.0%) 2.35% $1,980,000 2023-05-08
Q4 2022 Added 1,500,000 +200,000 (15.4%) 2.69% $2,250,000 2023-02-09
Q3 2022 Unchanged 1,300,000 0 (0.0%) 1.71% $1,534,000 2022-11-04
Q2 2022 Added 1,300,000 +525,000 (67.7%) 1.56% $1,469,000 2022-08-08
Q1 2022 Unchanged 775,000 0 (0.0%) 1.95% $2,317,000 2022-05-09
Q4 2021 Added 775,000 +25,000 (3.3%) 1.55% $2,054,000 2022-02-02
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

187 managers reported RIGEL PHARMACEUTICALS INC for Q3 2026.

Managers reporting RIGEL PHARMACEUTICALS INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 2,065,776 +125,958 < 0.01% $99,467,127 9 qtrs
Soleus Capital Management L P Unchanged 1,843,504 0 3.16% $88,764,718 10 qtrs
ARMISTICE CAPITAL LLC Reduced 1,536,000 -136,000 0.91% $73,958,400 10 qtrs
MORGAN STANLEY Added 1,256,819 +1,070,770 < 0.01% $60,515,834 10 qtrs
AMERICAN CENTURY COMPANIES INC Added 1,043,966 +302,248 0.02% $50,266,963 6 qtrs
STATE STREET CORPORATION Reduced 879,862 -160,132 < 0.01% $42,365,355 10 qtrs
LSV ASSET MANAGEMENT Added 787,408 +65,742 0.07% $37,914,000 6 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Reduced 782,703 -2,404 < 0.01% $37,687,149 3 qtrs
Assenagon Asset Management S A New 535,685 +535,685 0.02% $25,793,233 1 qtr
GEODE CAPITAL MANAGEMENT LLC Reduced 482,976 -199 < 0.01% $23,260,958 10 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 12, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
250,000
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.